Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.05) EPS and Q4 2025 earnings at ($0.05) EPS.

CNTX has been the topic of several other research reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, January 15th. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Finally, JMP Securities initiated coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Stock Up 0.2 %

Shares of CNTX opened at $0.77 on Friday. The company has a market cap of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06. Context Therapeutics has a twelve month low of $0.64 and a twelve month high of $2.75. The company has a 50 day moving average of $0.85 and a two-hundred day moving average of $1.43.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. On average, sell-side analysts expect that Context Therapeutics will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth about $52,000. MPM Bioimpact LLC purchased a new position in Context Therapeutics in the fourth quarter valued at approximately $15,441,000. Millennium Management LLC raised its stake in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after purchasing an additional 34,835 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter valued at approximately $31,000. Finally, Allostery Investments LP purchased a new stake in shares of Context Therapeutics during the fourth quarter valued at approximately $998,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.